Customedia Technologies, L.L.C. v. Dish Network Corporation

CourtDistrict Court, E.D. Texas
DecidedDecember 29, 2022
Docket2:16-cv-00129
StatusUnknown

This text of Customedia Technologies, L.L.C. v. Dish Network Corporation (Customedia Technologies, L.L.C. v. Dish Network Corporation) is published on Counsel Stack Legal Research, covering District Court, E.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Customedia Technologies, L.L.C. v. Dish Network Corporation, (E.D. Tex. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS MARSHALL DIVISION

CUSTOMEDIA TECHNOLOGIES, L.L.C., § §

§ Plaintiff, §

§ v. § CIVIL ACTION NO. 2:16-CV-00129-JRG

§ DISH NETWORK CORPORATION, DISH § NETWORK LLC, §

§ Defendants. §

MEMORANDUM OPINION AND ORDER Before the Court is Defendants DISH Network Corporation and DISH Network L.L.C.’s (collectively, “Defendants” or “DISH”) Motion to Declare the Case Exceptional Pursuant to 35 U.S.C. § 285 and Supporting Brief (the “Motion”). (Dkt. No. 215). Having considered the briefing, case record, and relevant authorities, the Court is of the opinion that the Motion should be DENIED for the reasons set forth herein. I. PROCEDURAL BACKGROUND On February 10, 2016, Plaintiff Customedia Technologies, L.L.C. (“Plaintiff” or “Customedia”) filed the above-captioned case against Defendants alleging Defendants infringed patents owned by Plaintiff. (Dkt. No. 1). Defendants subsequently filed petitions with the United States Patent and Trademark Office (“PTO”) challenging Plaintiff’s asserted patents. (See Dkt. No. 58). Specifically, Defendants filed six petitions for inter partes review (“IPR”) and four petitions for covered business method review (“CBMR”) challenging all 96 of the asserted claims. (Dkt. No. 58, Exs. B, C). After filing the petitions, Defendants requested the Court stay this case, and the Court declined to do so as the petitions had not yet been instituted. (Dkt. No. 112). However, on August 9, 2017, the Patent Trial and Appeal Board (“PTAB”) instituted review on all of Defendants’ petitions, and, despite Plaintiff’s opposition, the Court granted Defendants’ Renewed Motion to Stay (the “Motion to Stay”). (Dkt. No. 187). Plaintiff opposed the Motion Stay on the basis that the case was just weeks away from trial. (Dkt. No. 184). No asserted claim survived the Defendants’ challenges before the PTAB or the subsequent affirmance on appellate review by the Federal Circuit. (Dkt. Nos. 202-4, 202-5, 202-6, 202-7–202-

19, 202-26, 202-27). In other words, all of the claims Plaintiff elected to assert at trial before this Court have now been invalidated and cancelled. Thereafter, Plaintiff appealed the PTAB Final Written Decisions to the Federal Circuit. (Dkt. Nos. 215–1, 215–3). The Federal Circuit affirmed the PTAB’s decisions and denied Plaintiff’s petitions for rehearing and rehearing en banc. (Dkt. Nos. 201 at 3, 201–2, 201–12, 201– 13, 201–14, and 201–15). On July 31, 2020, Plaintiff filed a petition for writ of certiorari (the “Supreme Court Petition”) to the United States Supreme Court seeking a review of three questions: 1. Whether a court of appeals can invoke forfeiture to refuse to address an Appointments Clause violation in a pending appeal despite an intervening change in law.

2. Whether the PTAB exceeded its statutory authority under the Leahy-Smith America Invents Act and deprived Customedia of due process when the PTAB changed the petitioner's asserted grounds for review in the final written decision.

3. Whether claims to computer systems reciting the addition of specific computer hardware, which alters and interferes with the conventional operation of the computer system, are directed to patent-eligible subject matter within the meaning of 35 U.S.C § 101.

(Dkt. No. 227-9).

In response to the Supreme Court Petition, Defendants filed a single page waiver indicating they would not file a response. (Dkt. No. 227–10). The Supreme Court Petition was denied. (Dkt. No. 227 at 21). Thereafter, and following the Supreme Court’s decision in United States v. Arthrex, Inc., 594 U. S. ___, 141 S. Ct. 1970, 210 L. Ed. 2d 268 (2021) (“Arthrex II”), the PTO issued “interim” guidelines for seeking a rehearing of the PTAB’s decisions. On or before September 7, 2021, Plaintiff filed petitions under 37 CFR §§ 1.181, 1.182, and 1.183 (the “PTAB Petitions”) seeking a waiver and suspension of certain timing requirement under the interim guidelines in order to

request a rehearing based on Arthrex II. (Dkt. Nos. 202–20, 202–21, and 202–22). In response, Defendants filed oppositions, which were subsequently expunged by the PTO because the filing of an opposition or reply to a petition is not authorized absent PTAB approval, which Defendants failed to obtain. (Dkt. Nos. 227–27, 227–28). On June 14, 2022, the PTAB issued orders denying Plaintiff’s PTAB Petitions. (Dkt. Nos. 207–1, 207–2). On November 12, 2021, approximately seven months before the denial of the PTAB Petitions, Defendants filed a motion seeking a dismissal of this case with prejudice and entry of a final judgment. (Dkt. No. 202). Plaintiff opposed arguing that: Defendants prematurely ask the Court to enter a judgment dismissing this action against Defendants with prejudice. Lifting the stay of this case is inappropriate because the instituted post-grant review proceedings regarding the asserted patents—the reason why the Court stayed this case in the first place—have not been finally resolved in the [USPTO]. [Plaintiff] is currently seeking administrative remedies to achieve a final resolution following the Supreme Court’s guidance in United States v. Arthrex, Inc., 141 S. Ct. 1970 (2021). (Dkt. No. 203 at 1). On January 7, 2022, the Court carried the motion to allow Plaintiff’s Arthrex challenges to be reviewed by the Director of the USPTO. (Dkt. No. 206). On June 21, 2022, Defendants filed a status report advising that on June 14, 2022, the PTAB denied Plaintiff’s administrative Arthrex challenges for all asserted patents. (Dkt. No. 207 at 1–2). Plaintiff disagreed and argued that “the Director of the [USPTO] has not resolved Plaintiff’s administrative Arthrex challenges.” (Id. at 3). In an effort to bring this nearly seven-year case to an appropriate end while also affording the Director “a reasonable time during which [she] might personally review the Board’s decisions, while also avoiding an open-ended situation given the Director may elect never to review these matters personally,” the Court again carried the Motion for an additional thirty days. (Dkt. No. 208 at 2). On August 10, 2022, the Court entered its Order and Final Judgment dismissing the above-

captioned case with prejudice and entering judgment in Defendants’ favor. (Dkt. No. 216). Thereafter, Defendants filed their Motion seeking a declaration that this case is exceptional under 35 U.S.C. § 285 and an award of attorneys’ fees against Plaintiff and its counsel, jointly and severally, in the amount of $550,000.00. (Dkt. No. 215). II. LEGAL STANDARD In “exceptional cases,” a district court “may award reasonable attorney fees to the prevailing party” pursuant to the Patent Act. 35 U.S.C. § 285. An “exceptional case” is “simply one that stands out from others with respect to the substantive strength of a party’s litigating position . . . or the unreasonable manner in which the case was litigated.” Octane Fitness, LLC v. ICON Health & Fitness, Inc., 134 S. Ct. 1749, 1756 (2014); see also Highmark Inc. v. Allcare Health Mgmt. Sys., Inc., 134 S. Ct. 1744

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Fogerty v. Fantasy, Inc.
510 U.S. 517 (Supreme Court, 1994)
Forcillo v. Lemond Fitness, Inc.
168 F. App'x 429 (Federal Circuit, 2006)
Soverain Software LLC v. Amazon. Com, Inc.
356 F. Supp. 2d 660 (E.D. Texas, 2005)
Highmark Inc. v. Allcare Health Management System, Inc.
134 S. Ct. 1744 (Supreme Court, 2014)
Checkpoint Systems, Inc. v. All-Tag Security S.A.
858 F.3d 1371 (Federal Circuit, 2017)
United States v. Arthrex, Inc.
594 U.S. 1 (Supreme Court, 2021)
AstraZeneca AB v. Aurobindo Pharma Ltd.
232 F. Supp. 3d 636 (D. Delaware, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Customedia Technologies, L.L.C. v. Dish Network Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/customedia-technologies-llc-v-dish-network-corporation-txed-2022.